crimeancongo
hemorrhag
fever
cchf
acut
infecti
diseas
wide
geograph
distribut
averag
case
fatal
rate
approxim
etiolog
agent
cchf
orthonairoviru
cchfv
belong
orthonairoviru
genu
nairovirida
famili
cchfv
genom
consist
triseg
negativesens
rna
refer
small
medium
larg
l
segment
encod
nucleocapsid
protein
n
glycoprotein
precursor
gpc
viral
rnadependentrnapolymeras
l
respect
cchfv
primarili
maintain
transmit
tick
hyalomma
genu
ixodida
famili
viru
wide
host
rang
caus
transient
viremia
mani
wild
domest
laboratori
mammal
human
usual
acquir
infect
tick
bite
unprotect
contact
bodi
fluid
infect
anim
human
addit
sever
nosocomi
outbreak
report
contrast
human
adult
immunocompet
mammal
yet
report
develop
sign
diseas
impair
anim
model
develop
hamper
test
medic
countermeasur
cchf
cchfv
interferonsensit
viru
replic
highli
reduc
treatment
interferon
interferonsign
compet
cell
observ
led
discoveri
adult
mice
gene
knockout
interferon
signal
pathway
signal
transduc
activ
interferon
receptor
ifnar
mous
strain
highli
suscept
cchfv
infect
mimick
hallmark
human
diseas
cchf
consid
endem
countri
throughout
african
contin
balkan
middl
east
southern
russia
western
asia
past
year
cchf
emerg
reemerg
sever
countri
often
dramat
increas
case
number
furthermor
mark
increas
import
case
cchf
european
south
asian
countri
root
caus
increas
cchf
incid
rate
fulli
understood
factor
shift
climat
pattern
anim
human
migratori
pattern
popul
increas
livestock
wildlif
accompani
chang
agricultur
practic
increas
land
use
may
respons
thu
press
need
develop
prophylact
therapeut
countermeasur
signific
emerg
zoonosi
past
year
sever
vaccin
candid
evalu
protect
efficaci
preclin
studi
among
vaccin
base
dna
viral
subunit
whole
inactiv
viru
viruslik
particl
vlp
viral
vector
modifi
vaccinia
viru
ankara
mva
full
protect
lethal
cchfv
challeng
mous
model
achiev
dna
plasmid
express
gpc
subunit
n
well
mva
vector
express
gpc
open
read
frame
partial
protect
observ
whole
inactiv
viru
prepar
dna
plasmid
express
gpc
vlp
consist
n
gpc
l
combin
plasmid
dna
gpc
subunit
n
vlp
vaccin
approach
protect
achiev
solubl
glycoprotein
subunit
vaccin
mva
express
cchfv
n
overal
studi
implic
immun
respons
glycoprotein
import
protect
howev
glycoprotein
subunit
platform
shown
protect
despit
induc
signific
antibodi
respons
due
high
genet
divers
surfac
glycoprotein
amino
acid
ident
cchfv
strain
broadli
efficaci
vaccin
may
need
addit
genet
conserv
cchfv
antigen
n
amino
acid
ident
cchfv
strain
construct
character
experiment
cchf
vaccin
vector
base
human
adenoviru
type
ad
express
cchfv
n
adn
follow
infect
recombin
adn
cchfv
n
protein
detect
cell
lysat
mice
immun
adn
develop
antin
humor
immun
respons
singl
dose
adn
result
protect
ifnar
mice
lethal
cchfv
challeng
could
improv
primeboost
regimen
protect
result
indic
signific
role
n
protect
compon
cchfv
vaccin
anim
experi
approv
institut
anim
care
use
committe
rocki
mountain
laboratori
rml
perform
follow
guidelin
associ
assess
accredit
laboratori
anim
care
intern
aaalac
certifi
staff
aaalac
approv
facil
procedur
involv
infecti
cchfv
perform
rml
biosafeti
level
bsl
facil
standard
oper
procedur
sop
includ
sampl
inactiv
approv
institut
biosafeti
committe
ibc
cchfv
strain
ibar
kindli
provid
univers
texa
medic
branch
galveston
tx
usa
time
michael
holbrook
propag
scott
white
cell
maintain
leibovitz
medium
atcc
supplement
heatinactiv
fetal
bovin
serum
fb
mm
lglutamin
uml
penicillin
streptomycin
sigmaaldrich
environ
enrich
adenoviru
ad
express
complet
open
read
frame
orf
n
cchfv
strain
ibar
adn
ncbi
ref
seq
nucleotid
wild
type
ad
adwt
construct
rescu
use
adenox
adenovir
system
titer
use
adenox
rapid
titer
kit
accord
manufactur
instruct
clontech
ad
propag
cell
atcc
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fb
mm
lglutamin
uml
penicillin
streptomycin
obtain
sigmaaldrich
cell
infect
adwt
adn
multipl
infect
moi
cell
lysat
harvest
scrape
pbstween
pbst
day
post
infect
immunoblot
analysi
sdspage
sampl
mix
sdspage
load
buffer
vv
boil
minut
centrifug
appli
sdspage
protein
blot
onto
nylon
membran
ge
healthcar
follow
block
overnight
milkpbst
solut
membran
incub
rabbit
antin
peptid
polyclon
serum
thermo
fisher
scientif
inc
follow
goat
antirabbit
hrp
conjug
antiserum
detect
perform
use
pierc
ecl
plu
western
blot
substrat
thermo
fisher
scientif
inc
accord
manufactur
protocol
ifnar
mice
background
obtain
inhous
breed
coloni
group
ifnar
mice
n
rang
anim
per
group
vaccin
infecti
unit
ifu
adwt
adn
intramuscular
rout
deliv
hindleg
musculatur
day
primeonli
day
primeboost
group
total
volum
ifnar
mice
primeboost
experi
boost
week
day
post
vaccin
ifu
homolog
ad
construct
intranas
rout
per
nostril
mice
boost
intranas
rout
vaccin
regimen
previous
shown
bypass
preexist
ad
vector
immun
stimul
robust
immun
respons
ad
encod
antigen
vaccin
mice
acclimat
environ
day
prior
cchfv
challeng
four
week
vaccin
boost
day
ifnar
mice
challeng
cchfv
subcutan
rout
deliv
intrascapular
region
total
volum
anim
monitor
daili
clinic
sign
group
weight
record
day
post
infect
cchfv
mice
distinct
group
exsanguin
cardiac
punctur
anesthesia
whole
blood
collect
edta
tube
bd
bioscienc
rna
extract
frozen
viru
isol
liver
spleen
specimen
collect
patholog
evalu
immedi
frozen
viru
isol
remain
mice
n
per
vaccin
group
monitor
daili
day
post
infect
antibodi
igg
detect
use
elisa
base
whole
cchfv
particl
antigen
supernat
cchfv
infect
posit
antigen
mockinfect
neg
antigen
cell
harvest
clear
cell
debri
lowspe
centrifug
dilut
pbst
treat
gammairradi
mrad
maxisorp
plate
thermo
fisher
scientif
inc
coat
posit
neg
antigen
skim
milk
pbst
overnight
mous
serum
serial
dilut
twofold
start
dilut
ad
plate
incub
hour
room
temperatur
detect
perform
use
goat
antimous
peroxidaseconjug
igg
kpl
dilut
follow
treatment
abt
peroxidas
substrat
system
kpl
per
manufactur
instruct
cutoff
set
standard
deviat
read
neg
sampl
data
report
invers
dilut
cchfv
segment
specif
quantit
rtpcr
tissu
titrat
carri
previous
describ
tissu
sampl
treat
fix
formalin
accord
approv
standard
oper
procedur
fix
sampl
process
either
stain
hematoxylin
eosin
h
e
polyclon
antiserum
histopatholog
ihc
respect
describ
previous
slide
examin
veterinari
pathologist
score
follow
obviou
patholog
chang
minim
increas
number
inflammatori
cell
hepatocellular
necrosi
mildli
increas
number
inflammatori
cell
hepatocellular
necrosi
lymphocytolysi
moder
increas
number
inflammatori
cell
hepatocellular
necrosi
lymphocytolysi
highli
increas
number
inflammatori
cell
multifoc
hepatocellular
necrosi
lymphocytolysi
physiolog
paramet
compar
analyz
use
oneway
twoway
analysi
varianc
anova
dunnet
posttest
graphpad
prism
graphpad
softwar
confluent
cell
infect
adwt
adn
moi
express
cchfv
n
verifi
cell
lysat
adninfect
cell
immunoblot
use
nspecif
antiserum
fig
determin
immunogen
cchfv
n
immunocompromis
host
ifnar
mice
n
vaccin
intramuscularli
adn
ifu
follow
intranas
boost
ifu
four
week
later
seroconvers
assess
igg
elisa
three
mice
develop
detect
igg
antibodi
respons
cchfv
n
titer
fig
ifnar
mice
vaccin
intramuscularli
recombin
adenovirus
ifu
day
cchfv
challeng
mice
vaccin
adwt
n
rapidli
lost
weight
succumb
infect
within
day
fig
vaccin
adn
n
result
partial
protect
lethal
cchfv
challeng
surviv
p
reduc
clinic
sign
ie
weight
loss
increas
surviv
time
day
vs
day
surviv
adn
vs
ad
vaccin
p
mice
succumb
infect
fig
primeboost
strategi
employ
next
prime
administ
intramuscularli
boost
intranas
strategi
result
enhanc
protect
efficaci
ifnar
mice
immun
day
ifu
boost
day
ifu
recombin
adenovirus
challeng
day
cchfv
monitor
surviv
singledos
vaccin
adwt
vaccin
mice
n
rapidli
lost
weight
succumb
infect
day
post
infect
fig
adn
vaccin
anim
n
show
increas
protect
lethal
cchfv
challeng
surviv
p
reduc
clinic
sign
includ
weight
loss
increas
surviv
time
mice
succumb
infect
fig
day
post
cchfv
challeng
mice
n
euthan
liver
spleen
blood
sampl
viru
load
titrat
histopatholog
contrast
adwt
vaccin
anim
ifnar
mice
vaccin
adn
either
singledos
primeboost
approach
show
detect
viremia
analyz
quantit
rtpcr
viru
infect
assay
fig
notabl
liver
spleen
viral
load
day
post
infect
anim
vaccin
singl
dose
adn
similar
detect
adwt
vaccin
anim
fig
contrast
liver
spleen
viral
load
significantli
reduc
follow
primeboost
vaccin
adn
observ
promin
spleen
yet
unknown
reason
fig
adwt
vaccin
mice
develop
multifoc
coalesc
hepatocellular
necrosi
infiltr
viabl
degener
neutrophil
liver
fig
spleen
demonstr
mild
mark
acut
necrot
spleniti
loss
lymphocyt
fig
shown
previous
cchfvinfect
ifnar
mice
ifnar
mice
vaccin
singl
dose
adn
less
sever
hepat
lesion
compar
adwt
vaccin
anim
consist
mild
focal
necrosi
infiltr
small
number
viabl
degener
neutrophil
fig
splenic
lesion
detect
fig
result
improv
primeboost
vaccin
result
reduct
hepat
lesion
fig
absenc
splenic
lesion
fig
ihc
demonstr
high
amount
cchfv
n
antigen
liver
spleen
anim
immun
adwt
vector
fig
fig
wherea
mice
immun
adn
show
strongli
reduc
number
cchfv
antigenposit
cell
liver
spleen
lowest
number
anim
vaccin
primeboost
regimen
fig
fig
antigenposit
scatter
throughout
liver
spleen
associ
cell
morpholog
consist
hepatocyt
kupffer
cell
macrophag
endotheli
cell
previous
report
due
high
case
fatal
rate
potenti
humantohuman
transmiss
increas
likelihood
import
case
expand
endem
region
cchfv
seriou
threat
public
health
recogn
world
health
organ
ad
cchfv
list
prioriti
pathogen
http
wwwwhointblueprintprioritydiseasesen
therefor
develop
evalu
countermeasur
especi
vaccin
critic
import
mitig
detriment
impact
cchf
cchf
diseas
model
certain
immunocompromis
andor
human
mous
strain
mous
strain
includ
interferon
signal
defici
ifnar
mous
strain
human
mice
express
certain
human
cytokin
human
leukocyt
howev
diseas
progress
somewhat
atyp
diseas
primarili
neurolog
ifnar
mice
possess
complet
set
murin
immun
system
cell
either
alter
respons
interferon
signal
respond
type
interferon
signal
respect
lead
rapid
diseas
reminisc
human
hemorrhag
fever
ifnar
mice
highli
suscept
sever
diseas
caus
sever
viral
agent
due
lower
andor
alter
immun
respons
infect
compar
wild
type
mice
ifnar
mice
frequent
respond
quickli
infect
wild
type
mice
furthermor
cchfv
replic
higher
level
wild
type
mice
increas
difficulti
protect
ifnar
mice
infect
seem
associ
insuffici
immun
respons
due
inadequ
crossprim
antigen
present
cell
thu
efficaci
test
vaccin
model
difficult
protect
vaccin
must
elicit
proper
immun
respons
circumv
ifnar
dampen
antigen
prime
must
stimul
effect
adapt
immun
respons
compens
lack
antivir
state
activ
reduct
cchfv
replic
normal
mediat
type
interferon
signal
therefor
ifnar
mice
consid
higher
bar
efficaci
test
vaccin
fulli
immunocompet
rodent
model
cchfv
vaccin
develop
complic
limit
inform
b
tcell
epitop
requir
develop
effect
immun
respons
type
immun
respons
necessari
protect
diseas
mva
plasmid
dna
vlp
vaccin
platform
success
protect
mice
lethal
cchfv
challeng
protect
afford
depend
humor
cellmedi
immun
addit
platform
strongli
suggest
immun
respons
direct
gpc
whether
antibodi
cell
driven
essenti
protect
rodent
vaccin
regimen
focu
singl
antigen
success
ideal
vaccin
candid
would
facilit
immun
respons
multipl
antigen
achiev
protect
dose
possibl
ad
vector
known
elicit
strong
humor
cell
mediat
immun
respons
ifnar
mice
therefor
adbas
platform
util
address
whether
ifnar
mice
protect
lethal
cchfv
infect
use
conserv
cchfv
n
antigen
studi
ifnar
mice
vaccin
adn
develop
igg
respons
cchfv
n
fig
partial
protect
cchfv
challeng
fig
fig
due
lack
gpc
antigen
vaccin
prepar
protect
unlik
mediat
neutral
antibodi
rather
due
prime
tcell
andor
nonneutr
antibodi
respons
previous
report
ad
platform
ifnar
vaccin
studi
addit
experi
requir
demonstr
cell
andor
antibodi
respons
vaccinationinfect
respons
protect
sever
studi
evalu
correl
protect
ifnar
mice
cchfv
infect
role
adapt
immun
respons
follow
mva
immun
evalu
use
transfer
antibodi
andor
tcell
ifnar
mice
vaccin
studi
employ
dna
vlp
vaccin
evalu
use
circul
cytokin
profil
andor
igg
subtyp
ratio
altern
experi
select
deplet
b
tcell
popul
follow
vaccin
could
also
determin
import
two
arm
adapt
immun
system
respons
ad
vaccin
howev
import
caution
despit
util
appropri
earli
stage
vaccin
test
ifnar
mice
sever
immunocompromis
inbr
mice
therefor
may
gener
differ
protect
immun
respons
immunocompet
outbr
popul
human
andor
anim
dna
mva
platform
demonstr
protect
potenti
gpc
vaccin
studi
util
n
sole
antigen
rare
nonprotect
thu
protect
adn
demonstr
provid
critic
inform
futur
develop
cchf
vaccin
suggest
adn
protect
mechan
distinct
perhap
complimentari
mva
dna
platform
identif
protect
adbas
vaccin
could
therefor
critic
develop
effect
cchfv
combin
vaccin
regimen
addit
uncov
immun
target
mechan
protect
due
zoonot
natur
cchf
limit
potenti
persontoperson
transmiss
massscal
vaccin
unlik
use
case
cchf
howev
recent
report
ebola
efficaci
vaccin
hand
emerg
help
contain
outbreak
protect
medic
staff
attend
patient
end
readili
avail
vaccin
stockpil
effici
produc
accept
shelflif
effici
deliv
patient
clinic
staff
outbreak
region
undergon
least
clinic
phase
ii
test
would
great
import
sporad
lifethreaten
emerg
infecti
diseas
cchf
ad
platform
fulfil
criteria
addit
vaccin
consid
vaccin
stockpil
conclus
report
partial
protect
efficaci
adbas
vaccin
vector
express
cchfv
n
adn
lethal
cchfv
challeng
highli
suscept
immunocompromis
mous
model
partial
efficaci
follow
primeboost
vaccin
strategi
mediat
conserv
cchfv
antigen
demonstr
critic
role
protect
suggest
futur
consider
cchfv
vaccin
strategi
